Salesforce

Measure Paper - CMS 2022 Measure 135v10 for NextGen Office

« Go Back

Information

 
Application Version
Program/Measure YearMIPS 2022
Build Version
Document Summary
DomainEffective Clinical Care
Measure NameHeart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)     
DescriptionPercentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge.
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
KeywordseCQM CMS135 "heart failure" HF "left ventricular ejection fraction" LVEF LVSD "angiotensin-converting enzyme" "ACE inhibitor" "angiotensin receptor blocker" ARB "angiotensin receptor-neprilysin inhibitor" ARNI MIPS
TitleMeasure Paper - CMS 2022 Measure 135v10 for NextGen Office
URL NameCMS135

Powered by